Figure 4
From: Essential role of proteasomes in maintaining self-renewal in neural progenitor cells
Appearance of senescence-like phenotypes in NPCs exposed to the proteasomal inhibitor MG132.
(A) The number of proliferating cells in the SVZ was quantified by BrdU labeling 7 days after intraventricular injection with 10 μg MG132 or the vehicle DMSO. Notably, MG132 injection robustly inhibited NPCs proliferation in vivo (a), concurrent with a reduced proteasomal activity (b). (B) NPCs from E14 mice incubated with 0.2 μM MG132 for 24 hrs formed fewer neurospheres. (C) BrdU incorporation indicated a retarded proliferation of NPCs after an 8-hr treatment with MG132. The percentage of BrdU+ cells was reduced in a concentration-dependent manner. (D) After exposing NPCs to MG132 for 5 hrs, the cell viability was decreased in a concentration-dependent manner as measured by CCK-8 assay. (E) Tuj1 staining showed that treatment with MG132 attenuated the neuronal differentiation of NPCs in vitro. **p < 0.01 vs. DMSO control.
